Hyperion DeFi reported a net income of $39.6 million in Q3, a significant increase from $6.63 million a year earlier. The company reduced its HYPE token holdings from 2.04 million to about 1.848 million by selling tokens to repay debt, with remaining tokens valued at $167.9 million. Revenue rose 168% year-over-year to $810,000, while adjusted EBITDA was $48.66 million, slightly down from Q2 due to a $5.7 million adjustment. Hyperion cleared its historical debt, repaid $8.6 million on a loan, repurchased shares, and maintained strong staking yields, reaffirming its 2026 adjusted gross profit guidance of $7 million to $8 million.
Hyperion DeFi's Q3 profit and token activity provide context for readers. For those following major cryptocurrencies on Pluang, 6 out of 50 rose while 43 fell. Notable moves include BAL up 11.14% to Rp16.297 and SXP down 46.27% to Rp37, as of Nov 12, 2026 23:41 WIB.
D.A. Davidson raised Riskified's price target to $12, reflecting a 22.2% potential upside from $9.82. The company reported a 41% revenue increase to $115.2 million and adjusted earnings of $0.07 per share, beating estimates. Profitability improved wi...
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
